CS-1103, a new drug that binds methamphetamine deactivating it on contact, could revolutionize treatment for meth poisoning, which currently relies on sedation. The new medication also binds fentanyl and cocaine, and following injection, ensures patients are free from drug influences within minutes, facilitating treatment for underlying issues and potential withdrawal management. Having proved safe in Phase 1 FDA clinical trials, CS-1103 is due for emergency department use by mid-2026.
GP2GP likely to be phased out and more briefs
Te Whatu Ora plans to address risks of the outdated GP2GP electronic record system until a new digital health record launches midyear. In Western Australia,
